皮层表面铁沉积与脑淀粉样血管病出血风险的荟萃分析
该荟萃分析纳入6项临床队列共1239例有症状的脑淀粉样血管病(CAA)患者,基线均行T2*磁共振并随访未来脑出血(ICH)。结果显示cSS总患病率34%,随访平均3.1年ICH年发生率为6.9%;存在cSS者ICH风险独立增加(adjHR 2.14),播散性cSS风险最高(adjHR 4.28)。
要点
- cSS是CAA患者未来ICH的重要MRI预后风险因素
- 播散性cSS(累及>3个脑沟)出血风险最高
- cSS的存在与范围有助于CAA患者的治疗规划
核心结论
- 在CAA患者中,cSS的存在和范围是未来ICH最重要的MRI预后风险因素,可能有助于治疗规划。
研究设计与样本
- 本研究为荟萃分析,纳入6项临床队列共1239例有症状的CAA患者,基线均有T2*磁共振并接受未来ICH的临床随访。
- 采用两阶段随机效应模型合并数据,并使用多变量Cox比例风险模型得出的协变量校正风险比(adjHR)。
主要发现
- cSS总患病率为34%(95%CI 26%-41%);局灶性cSS患病率14%(95%CI 12%-16%),播散性cSS患病率20%(95%CI 13%-26%)。
- 平均随访3.1年(范围1-4年)期间,162/1239例患者发生症状性ICH,合并年发生率为6.9%(95%CI 3.9%-9.8%)。
- 无cSS患者ICH年发生率为3.9%(95%CI 1.7%-6.1%),存在cSS者为11.1%(95%CI 7%-15.2%),局灶性cSS者为9.1%(95%CI 5.5%-12.8%),播散性cSS者为12.5%(95%CI 5.3%-19.7%)。
- 校正后合并分析显示,任何cSS的存在与未来ICH风险增加独立相关(adjHR 2.14;95%CI 1.19-3.85;p<0.0001)。
- 局灶性cSS与ICH风险相关(adjHR 2.11;95%CI 1.31-2.41;p=0.002),播散性cSS出血风险最强(adjHR 4.28;95%CI 2.91-6.30;p<0.0001)。
关键数值与推荐
- 该研究提供Class III证据:在有症状的CAA幸存者中,基线T2*磁共振显示cSS(尤其是播散性,即累及>3个脑沟)增加未来ICH风险。
临床怎么用
- 对于有症状的CAA患者,应评估基线T2*磁共振上的cSS存在与范围,以辅助未来ICH风险分层和治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the association of cortical superficial siderosis (cSS) presence and extent with future bleeding risk in cerebral amyloid angiopathy (CAA). METHODS: This was a meta-analysis of clinical cohorts of symptomatic patients with CAA who had T2*-MRI at baseline and clinical follow-up for future intracerebral hemorrhage (ICH). We pooled data in a 2-stage meta-analysis using random effects models. Covariate-adjusted hazard ratios (adjHR) from multivariable Cox proportional hazard models were used. RESULTS: We included data from 6 eligible studies (n = 1,239). cSS pooled prevalence was 34% (95% confidence interval [CI] 26%-41%; I 2 87.94%; p < 0.001): focal cSS prevalence was 14% (95% CI 12%-16%; I 2 6.75%; p = 0.37), and disseminated cSS prevalence was 20% (95% CI 13%-26%; I 2 90.39%; p < 0.001). During a mean follow-up of 3.1 years (range 1-4 years), 162/1,239 patients experienced a symptomatic ICH-pooled incidence rate 6.9% per year (95% CI 3.9%-9.8% per year; I 2 83%; p < 0.001). ICH incidence rates per year according to cSS status were 3.9% (95% CI 1.7%-6.1%; I 2 70%; p = 0.018) for patients without cSS, 11.1% (95% CI 7%-15.2%; I 2 56.8%; p = 0.074) for cSS presence, 9.1% (95% CI 5.5%-12.8%; I 2 0%; p = 0.994) for focal cSS, and 12.5% (95% CI 5.3%-19.7%; I 2 73.2%; p = 0.011) for disseminated cSS. In adjusted pooled analysis, any cSS presence was independently associated with increased future ICH risk (adjHR 2.14; 95% CI 1.19-3.85; p < 0.0001). Focal cSS was linked with ICH risk (adjHR 2.11; 95% CI 1.31-2.41; p = 0.002), while disseminated cSS conferred the strongest bleeding risk (adjHR 4.28; 95% CI 2.91-6.30; p < 0.0001). CONCLUSION: In patients with CAA, cSS presence and extent are the most important MRI prognostic risk factors for future ICH, likely useful in treatment planning. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that in symptomatic CAA survivors with baseline T2*-MRI, cSS (particularly if disseminated, i.e., affecting >3 sulci) increases the risk of future ICH.
引用
- Charidimou A, Boulouis G, Greenberg SM, et al. Cortical superficial siderosis and bleeding risk in cerebral amyloid angiopathy: A meta-analysis. Neurology. 2019. PMID: 31732564. doi:10.1212/WNL.0000000000008590
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。